Maricann Group Inc. (CSE:MARI) (OTC:MRRCF) (FRA:75M) and a national provider that services pharmacies across Canada, announced that they have entered into a definitive agreement to create a pharmacy services program that enables pharmacists to counsel and appropriately educate patients in relation to medicinal cannabis.

The new initiative will aim to position pharmacies as a preferred access point for medical marijuana based on pharmacists' critical role in working with physicians and patients in understanding the opportunities in multi-medication patients. Maricann will be working to help patients in achieving their desired treatment goals while always keeping their safety as the number one priority.

Maricann will develop additional medical cannabis product accessibility initiatives with the objective of establishing procedures and protocols for medicinal cannabis medical documents, and facilitating the submission of patient prescriptions to Maricann for direct to patient fulfillment.

"We are extremely excited about this important initiative. Pharmacists consistently rank at very high levels among the most trusted professionals, and this initiative will place participating pharmacists at the forefront of patient care as it relates to the use of medicinal cannabis," says Maricann CEO Ben Ward.

Maricann, which has federal licenses in Canada to cultivate, extract, formulate and distribute cannabis, is rapidly expanding its Canadian production, based in Norfolk County, Ontario, targeting to add 20,000 kg of dry flower production to come online in 2018, with additional production planned.

This announcement comes on the heels of Maricann's recent capital raise and deal with NanoLeaf Technologies.